Cargando…
Use of First-Line Oral Analgesics during and after COVID-19: Results from a Survey on a Sample of Italian 696 COVID-19 Survivors with Post-Acute Symptoms
HIGHLIGHTS: What are the main findings of the study? The most-used pain medication during COVID-19 is acetaminophen. The most common analgesics used in post-COVID-19 are acetaminophen, ibuprofen or other NSAID, while older subjects prefer acetaminophen. The frequency of pain medication is often seve...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10142362/ https://www.ncbi.nlm.nih.gov/pubmed/37109328 http://dx.doi.org/10.3390/jcm12082992 |
_version_ | 1785033594861780992 |
---|---|
author | Galluzzo, Vincenzo Zazzara, Maria Beatrice Ciciarello, Francesca Tosato, Matteo Bizzarro, Alessandra Paglionico, Annamaria Varriano, Valentina Gremese, Elisa Calvani, Riccardo Landi, Francesco |
author_facet | Galluzzo, Vincenzo Zazzara, Maria Beatrice Ciciarello, Francesca Tosato, Matteo Bizzarro, Alessandra Paglionico, Annamaria Varriano, Valentina Gremese, Elisa Calvani, Riccardo Landi, Francesco |
author_sort | Galluzzo, Vincenzo |
collection | PubMed |
description | HIGHLIGHTS: What are the main findings of the study? The most-used pain medication during COVID-19 is acetaminophen. The most common analgesics used in post-COVID-19 are acetaminophen, ibuprofen or other NSAID, while older subjects prefer acetaminophen. The frequency of pain medication is often several times a week. What is the implication of the main findings? The need to continue analgesic therapy after COVID-19 is associated with persistent arthralgia and myalgia. Most patients report an improvement in pain perception after taking analgesic therapy. ABSTRACT: Background—Analgesics could be used to manage painful symptoms during and after COVID-19. Materials and methods—Persistence of painful symptoms was assessed during and after COVID-19 in a sample of patients admitted to a post-acute COVID-19 outpatient service in Rome, Italy. Data on type and frequency of use of first-line analgesics were collected. Pain severity was evaluated with a numeric rating scale (NRS) from 0 to 10. Results—Mean age of 696 participants was 57.1 ± 20.3 years and 61.7% were women. During COVID-19, the most prevalent symptoms were fever, fatigue, arthralgia, myalgia and headache. Acetaminophen was used by 40% of the sample. Only 6.7% needed to continue analgesic therapy after COVID-19. Frequent causes of analgesics consumption were persistent arthralgia and myalgia. The most common analgesics used amongst those who continued taking analgesics in the post-acute phase of COVID-19 were the following: acetaminophen (31%), ibuprofen (31%) and other non-steroidal anti-inflammatory drug (NSAID) (29.5%); in older subjects the most common analgesic used was acetaminophen (54%). Most of the subjects in this group said there was an improvement in pain perception after taking analgesic therapy (84%). Conclusions—Use of analgesics in the post-acute COVID-19 is common in subjects with persistent arthralgia and myalgia, and common analgesics were acetaminophen and ibuprofen. Further research on the safety and efficacy of those medications in COVID-19 is warranted. |
format | Online Article Text |
id | pubmed-10142362 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-101423622023-04-29 Use of First-Line Oral Analgesics during and after COVID-19: Results from a Survey on a Sample of Italian 696 COVID-19 Survivors with Post-Acute Symptoms Galluzzo, Vincenzo Zazzara, Maria Beatrice Ciciarello, Francesca Tosato, Matteo Bizzarro, Alessandra Paglionico, Annamaria Varriano, Valentina Gremese, Elisa Calvani, Riccardo Landi, Francesco J Clin Med Article HIGHLIGHTS: What are the main findings of the study? The most-used pain medication during COVID-19 is acetaminophen. The most common analgesics used in post-COVID-19 are acetaminophen, ibuprofen or other NSAID, while older subjects prefer acetaminophen. The frequency of pain medication is often several times a week. What is the implication of the main findings? The need to continue analgesic therapy after COVID-19 is associated with persistent arthralgia and myalgia. Most patients report an improvement in pain perception after taking analgesic therapy. ABSTRACT: Background—Analgesics could be used to manage painful symptoms during and after COVID-19. Materials and methods—Persistence of painful symptoms was assessed during and after COVID-19 in a sample of patients admitted to a post-acute COVID-19 outpatient service in Rome, Italy. Data on type and frequency of use of first-line analgesics were collected. Pain severity was evaluated with a numeric rating scale (NRS) from 0 to 10. Results—Mean age of 696 participants was 57.1 ± 20.3 years and 61.7% were women. During COVID-19, the most prevalent symptoms were fever, fatigue, arthralgia, myalgia and headache. Acetaminophen was used by 40% of the sample. Only 6.7% needed to continue analgesic therapy after COVID-19. Frequent causes of analgesics consumption were persistent arthralgia and myalgia. The most common analgesics used amongst those who continued taking analgesics in the post-acute phase of COVID-19 were the following: acetaminophen (31%), ibuprofen (31%) and other non-steroidal anti-inflammatory drug (NSAID) (29.5%); in older subjects the most common analgesic used was acetaminophen (54%). Most of the subjects in this group said there was an improvement in pain perception after taking analgesic therapy (84%). Conclusions—Use of analgesics in the post-acute COVID-19 is common in subjects with persistent arthralgia and myalgia, and common analgesics were acetaminophen and ibuprofen. Further research on the safety and efficacy of those medications in COVID-19 is warranted. MDPI 2023-04-20 /pmc/articles/PMC10142362/ /pubmed/37109328 http://dx.doi.org/10.3390/jcm12082992 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Galluzzo, Vincenzo Zazzara, Maria Beatrice Ciciarello, Francesca Tosato, Matteo Bizzarro, Alessandra Paglionico, Annamaria Varriano, Valentina Gremese, Elisa Calvani, Riccardo Landi, Francesco Use of First-Line Oral Analgesics during and after COVID-19: Results from a Survey on a Sample of Italian 696 COVID-19 Survivors with Post-Acute Symptoms |
title | Use of First-Line Oral Analgesics during and after COVID-19: Results from a Survey on a Sample of Italian 696 COVID-19 Survivors with Post-Acute Symptoms |
title_full | Use of First-Line Oral Analgesics during and after COVID-19: Results from a Survey on a Sample of Italian 696 COVID-19 Survivors with Post-Acute Symptoms |
title_fullStr | Use of First-Line Oral Analgesics during and after COVID-19: Results from a Survey on a Sample of Italian 696 COVID-19 Survivors with Post-Acute Symptoms |
title_full_unstemmed | Use of First-Line Oral Analgesics during and after COVID-19: Results from a Survey on a Sample of Italian 696 COVID-19 Survivors with Post-Acute Symptoms |
title_short | Use of First-Line Oral Analgesics during and after COVID-19: Results from a Survey on a Sample of Italian 696 COVID-19 Survivors with Post-Acute Symptoms |
title_sort | use of first-line oral analgesics during and after covid-19: results from a survey on a sample of italian 696 covid-19 survivors with post-acute symptoms |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10142362/ https://www.ncbi.nlm.nih.gov/pubmed/37109328 http://dx.doi.org/10.3390/jcm12082992 |
work_keys_str_mv | AT galluzzovincenzo useoffirstlineoralanalgesicsduringandaftercovid19resultsfromasurveyonasampleofitalian696covid19survivorswithpostacutesymptoms AT zazzaramariabeatrice useoffirstlineoralanalgesicsduringandaftercovid19resultsfromasurveyonasampleofitalian696covid19survivorswithpostacutesymptoms AT ciciarellofrancesca useoffirstlineoralanalgesicsduringandaftercovid19resultsfromasurveyonasampleofitalian696covid19survivorswithpostacutesymptoms AT tosatomatteo useoffirstlineoralanalgesicsduringandaftercovid19resultsfromasurveyonasampleofitalian696covid19survivorswithpostacutesymptoms AT bizzarroalessandra useoffirstlineoralanalgesicsduringandaftercovid19resultsfromasurveyonasampleofitalian696covid19survivorswithpostacutesymptoms AT paglionicoannamaria useoffirstlineoralanalgesicsduringandaftercovid19resultsfromasurveyonasampleofitalian696covid19survivorswithpostacutesymptoms AT varrianovalentina useoffirstlineoralanalgesicsduringandaftercovid19resultsfromasurveyonasampleofitalian696covid19survivorswithpostacutesymptoms AT gremeseelisa useoffirstlineoralanalgesicsduringandaftercovid19resultsfromasurveyonasampleofitalian696covid19survivorswithpostacutesymptoms AT calvaniriccardo useoffirstlineoralanalgesicsduringandaftercovid19resultsfromasurveyonasampleofitalian696covid19survivorswithpostacutesymptoms AT landifrancesco useoffirstlineoralanalgesicsduringandaftercovid19resultsfromasurveyonasampleofitalian696covid19survivorswithpostacutesymptoms |